- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Second-generation antipsychotics increase risks of pregnancy complications

Finland: Prenatal exposure to second-generation antipsychotics (S-GAs) increases the risk of pregnancy complications relating to impaired glucose metabolism, a recent study in the European Journal of Clinical Pharmacology has suggested. Neonatal problems are common and occur similarly in both first-generation antipsychotic (F-GA) and S-GA users.
Because of the increasing use of S-GAs among pregnant women and conflicting data on their safety. Heli Malm, Helsinki University and Helsinki University Hospital, Tukholmankatu, Helsinki, Finland, and colleagues investigated the association between S-GA use during pregnancy and neonatal complications using nationwide register data.
The researchers conducted this population-based birth cohort study using national register data extracted from the "Drugs and Pregnancy" database in Finland, the years 1996–2016. The sampling frame included 1,181,090 pregnant women and their singleton births. Women were categorized into three groups -- exposed to S-GAs during pregnancy (n = 4225), exposed to first-generation antipsychotics (F-GAs) during pregnancy (n = 1576), and unexposed (no purchases of S-GAs or F-GAs during pregnancy, n = 21,125).
Pregnancy outcomes in S-GA users were compared with those in the two comparison groups using multiple logistic regression models.
Key findings of the study include:
- Comparing S-GA users with unexposed ones, the risk was increased for gestational diabetes (adjusted odds ratio, OR 1.43), cesarean section (OR 1.35), being born large for gestational age (LGA) (OR 1.57), and preterm birth (OR 1.29).
- The risk for these outcomes increased further with continuous S-GA use.
- Infants in the S-GA group were also more likely to suffer from neonatal complications.
- Comparing S-GA users with the F-GA group, the risk of cesarean section and LGA was higher (OR 1.25 and OR 1.89, respectively).
- Neonatal complications did not differ between the S-GA and F-GA groups.
"Prenatal exposure to second-generation antipsychotics is associated with an increased risk of pregnancy complications related to impaired glucose metabolism. Neonatal problems are common and occur similarly in S-GA and F-GA users," wrote the authors.
The study, "Second-generation antipsychotics and pregnancy complications," is published in the European Journal of Clinical Pharmacology.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751